ES2186704T3 - Uso de antagonistas de crf. - Google Patents

Uso de antagonistas de crf.

Info

Publication number
ES2186704T3
ES2186704T3 ES95201475T ES95201475T ES2186704T3 ES 2186704 T3 ES2186704 T3 ES 2186704T3 ES 95201475 T ES95201475 T ES 95201475T ES 95201475 T ES95201475 T ES 95201475T ES 2186704 T3 ES2186704 T3 ES 2186704T3
Authority
ES
Spain
Prior art keywords
formula
relationship
crf antagonists
pizazolopirimidinas
pirrolopicimidines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95201475T
Other languages
English (en)
Inventor
Gene M Bright
Yuhpyng L Chen
Willard M Welch Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2186704T3 publication Critical patent/ES2186704T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

PIRRAZOLOS SUSTITUIDOS DE FORMULA COMPUESTOS DE LA FORMULA PIRAZOLOS Y PIZAZOLOPIRIMIDINAS DE LA FORMULA Y PIRROLOPICIMIDINAS DE LA FORMULA QUE TIENEN UNA ACTIVIDAD ANTAGONISTA DE FACTOR LIBERADOR DE CORTICOTROPINA, QUE SON DE UTILIDAD EN EL TRATAMIENTO DE UNA VARIEDAD DE DESORDENES RELACIONADOS CON EL ESTRES.
ES95201475T 1994-06-15 1995-06-06 Uso de antagonistas de crf. Expired - Lifetime ES2186704T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/259,835 US5646152A (en) 1994-06-15 1994-06-15 Methods of administering CRF antagonists

Publications (1)

Publication Number Publication Date
ES2186704T3 true ES2186704T3 (es) 2003-05-16

Family

ID=22986605

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95201475T Expired - Lifetime ES2186704T3 (es) 1994-06-15 1995-06-06 Uso de antagonistas de crf.

Country Status (17)

Country Link
US (2) US5646152A (es)
EP (1) EP0691128B1 (es)
JP (1) JPH083041A (es)
KR (1) KR960000221A (es)
AT (1) ATE229334T1 (es)
AU (1) AU701963B2 (es)
CA (1) CA2151674C (es)
CZ (1) CZ294696B6 (es)
DE (1) DE69529121T2 (es)
DK (1) DK0691128T3 (es)
ES (1) ES2186704T3 (es)
HU (1) HUT71602A (es)
IL (1) IL114061A0 (es)
MY (1) MY115960A (es)
NZ (1) NZ272357A (es)
PT (1) PT691128E (es)
ZA (1) ZA954921B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6005109A (en) * 1997-10-30 1999-12-21 Pflizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
US6103900A (en) * 1992-12-17 2000-08-15 Pfizer Inc Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
DE59500788D1 (de) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
FI964893A7 (fi) * 1994-06-06 1996-12-05 Pfizer Substituoituja pyratsoleja, jotka ovat aktiivisia kortikotropiinin vap auttamistekijän (CRF) antagonisteina
EP0729758A3 (en) * 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US6664261B2 (en) 1996-02-07 2003-12-16 Neurocrine Biosciences, Inc. Pyrazolopyrimidines as CRF receptor antagonists
US6051578A (en) * 1996-02-12 2000-04-18 Pfizer Inc. Pyrazolopyrimidines for treatment of CNS disorders
US6022978A (en) * 1996-06-11 2000-02-08 Pfizer Inc. Benzimidazole derivatives
WO1998008382A1 (en) * 1996-08-30 1998-03-05 Eli Lilly And Company Nonclassical pyrrolo[2,3-d]pyrimidine antifolates
US5723608A (en) * 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
US6472402B1 (en) 1998-04-02 2002-10-29 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
AU3378799A (en) * 1998-04-02 1999-10-25 Neurogen Corporation Aminoalkyl substituted pyrrolo(2,3-b)pyridine and pyrrolo(2,3-d)pyrimidine derivatives: modulators of crf1 receptors
US6291473B1 (en) 1998-04-02 2001-09-18 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9H-pyridino [2, 3-B] indole and 5,6,7,8-tetrahydro-9H-pyrimidino [4, 5-B] indole derivatives: CRF1 specific ligands
KR100505394B1 (ko) * 1998-10-17 2005-10-26 주식회사 하이닉스반도체 웨이퍼수준 칩크기 반도체 패키지와 그 제조방법
US6432989B1 (en) * 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
CO5271670A1 (es) * 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
AU2001232271A1 (en) * 2000-02-14 2001-08-20 Japan Tobacco Inc. Preventives/remedies for postoperative stress
GB0016787D0 (en) * 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
WO2003048160A1 (en) * 2001-12-04 2003-06-12 F. Hoffmann-La Roche Ag Ring fused pyrazole derivatives
BR0316950A (pt) * 2002-12-02 2006-01-17 Hoffmann La Roche Derivados de indazol como antagonistas de crf
TWI270549B (en) 2002-12-26 2007-01-11 Taisho Pharmaceutical Co Ltd Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
PL2298743T3 (pl) 2003-06-26 2013-02-28 Novartis Ag Inhibitory kinaz P38 na bazie 5-członowych heterocykli
JP2007523109A (ja) * 2004-02-18 2007-08-16 エフ．ホフマン−ラ　ロシュ　アーゲー 複素環式Ｇａｂａ−Ａサブタイプ選択的レセプターモジュレーター
DE102006029074A1 (de) 2006-06-22 2007-12-27 Friedrich-Schiller-Universität Jena 4-Amino-3-arylamino-6-arylpyrazolo[3,4-d]pyrimidin-Derivate, Verfahren zu ihrer Herstellung und deren Verwendung als antivirale Wirkstoffe
JP5670113B2 (ja) 2010-08-02 2015-02-18 株式会社やまびこ 反転掃気式２サイクルエンジン
PL2766367T3 (pl) 2011-10-14 2022-08-22 Scandion Oncology A/S Pochodne 4-amino-3-fenyloamino-6-fenylopirazolo[3,4-d]pirymidyny do leczenia infekcji wirusowych, zwłaszcza infekcji pikornawirusowych
DE102012004736A1 (de) 2011-10-20 2013-04-25 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg 4-Amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidin-Derivate und deren Verwendung als antivirale Wirkstoffe

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3551428A (en) * 1956-02-10 1970-12-29 Ciba Geigy Corp New 1- (or 2-) substituted 4-mercapto-pyrazolo(3,4-d)pyrimidines
DE2430454A1 (de) * 1974-06-25 1976-01-15 Thomae Gmbh Dr K Neue pyrazolo eckige klammer auf 3,4d eckige klammer zu pyrimidine
US4139705A (en) * 1977-05-20 1979-02-13 The Dow Chemical Company Pyrazolopyrimidines
DE2818676A1 (de) * 1978-04-27 1979-11-08 Troponwerke Gmbh & Co Kg Substituierte 5,6-dimethylpyrrolo 2,3-d pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2460299A1 (fr) * 1979-07-05 1981-01-23 Bellon Labor Sa Roger Nouveaux derives du pyrazole et leur application therapeutique
DE3145287A1 (de) * 1981-11-14 1983-05-19 Troponwerke GmbH & Co KG, 5000 Köln Pyrrolo (2.3-d)pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4605642A (en) * 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
GB8432073D0 (en) * 1984-12-19 1985-01-30 Roussel Lab Ltd Chemical compounds
DE3712735A1 (de) * 1987-04-15 1988-11-10 Boehringer Mannheim Gmbh Neue pyrazolo(3,4-d)pyrimidine, verfahren zu ihrer herstellung und verwendung als arzneimittel
US4885300A (en) * 1988-03-03 1989-12-05 Ortho Pharmaceutical Corporation 4-Substituted pyrazolo[3,4-D]pyrimidine derivatives
US5063245A (en) * 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
JPH05196008A (ja) * 1991-11-20 1993-08-06 Myotoku Kk 空気圧動作装置とその制御装置
WO1993010715A2 (en) * 1991-12-03 1993-06-10 Vesitec Medical, Inc. Surgical treatment of stress urinary incontinence
IT222061Z2 (it) * 1991-12-03 1994-12-29 Hydro Aluminium Systems Spa Complesso di profilati metallici per serramenti muniti di squadrette di rinforzo
JPH0669494B2 (ja) * 1991-12-04 1994-09-07 南雄 河野 医療用窓付断熱カテーテル
FR2692893B1 (fr) * 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
KR19990067704A (ko) * 1992-12-17 1999-08-25 디. 제이. 우드, 스피겔 알렌 제이 부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물
CZ284157B6 (cs) * 1992-12-17 1998-08-12 Pfizer Inc. Pyrazolové a pyrazolopyrimidinové sloučeniny jako takové a pro léčbu chorob a farmaceutické prostředky na jejich bázi
TW336932B (en) * 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines

Also Published As

Publication number Publication date
DE69529121D1 (de) 2003-01-23
ZA954921B (en) 1996-12-17
US5646152A (en) 1997-07-08
IL114061A0 (en) 1995-10-31
CZ294696B6 (cs) 2005-02-16
AU701963B2 (en) 1999-02-11
DK0691128T3 (da) 2003-03-31
CA2151674A1 (en) 1995-12-16
CZ153795A3 (en) 1996-01-17
AU2169195A (en) 1995-12-21
NZ272357A (en) 1997-06-24
DE69529121T2 (de) 2003-04-24
CA2151674C (en) 1999-06-22
ATE229334T1 (de) 2002-12-15
EP0691128B1 (en) 2002-12-11
MY115960A (en) 2003-10-31
EP0691128A1 (en) 1996-01-10
JPH083041A (ja) 1996-01-09
HUT71602A (en) 1996-01-29
US6200979B1 (en) 2001-03-13
KR960000221A (ko) 1996-01-25
PT691128E (pt) 2003-02-28
HU9501738D0 (en) 1995-08-28

Similar Documents

Publication Publication Date Title
ES2186704T3 (es) Uso de antagonistas de crf.
ATE458814T1 (de) Menschliches zytokinrezeptor
ES2175066T3 (es) Antagonistas triciclicos de la vasopresina.
ES2124793T3 (es) Derivados de rapamicina alquilados en o y su uso, particularmente como inmunosupresores.
FI953748L (fi) Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina
FI941378L (fi) Bentsimidatsoliyhdisteitä, niiden käyttö ja valmistus
UY34152A (es) ?oxazolidinonas substituidas y su uso?.
DE69925133D1 (de) Pyrrolobenzodiazepine
PT1204663E (pt) Novos compostos espiro com actividade antagonista do neuropeptido y
MX9705296A (es) Compuestos novedosos de imidazol 1,4,5-susbtituidos y el uso de los mismos para preparar composiciones para uso en terapia.
BR9206237A (pt) Uso de derivados de tetrahidrocarbazole como receptores agonistas 5-HT1.
ES2129090T3 (es) Diazepinas triciclicas antagonistas de la vasopresina y de la oxitocina.
BR9810342A (pt) Novos compostos imidazola substituìdos
FI904659A7 (fi) Uusia bentsimidatsoliyhdisteitä ja niiden käyttö
BR9706934A (pt) Novos compostos de imidazol substituìdo
DE69818248D1 (de) Chinolin- und chinazolin-derivate als crf antagonisten
ES2154741T3 (es) Uso de agentes de union a cd23 en el tratamiento de enfermedades autoinmunes.
FI972629A7 (fi) Aryyli- ja heteroaryylisulfonamidijohdoksia, niiden valmistus ja niiden käyttö endoteliinin antagonisteina
FI962043L (fi) Substituoidut 5-rengas-heterosyklit, niiden valmistus ja niiden käyttö
ATE263242T1 (de) Aminoterminal verkürztes rantes als chemokin antagonist
FI944417L (fi) Atsoliyhdisteet, niiden valmistus ja käyttö
BR0009421A (pt) Inibidores de ligação lfa-1 aos icams e uso dos mesmos
FI925501A7 (fi) Imidatsoliyhdisteitä, niiden valmistus ja käyttö
ATE116980T1 (de) Verbesserungen an leukotrien-antagonieten.
TR200200357T2 (tr) Yeni integrin reseptör antagonistleri